ReleaseWire Connect

Drug makers are increasingly partnering with medical research centers and institutes to develop more effective peptide drugs. This, in turn, is projected to make a positively impact on the growth of the global peptide based gastrointestinal disorders therapeutics market in the near future.  A recent study conducted by Fact.MR reveals that the global market for peptide based gastrointestinal disorders therapeutics is poised to exhibit a strong CAGR during the forecast period (2017-2022), to reach a valuation in excess of US$ 600 Mn. Growing occurrence of metabolic disorders and gastrointestinal ailments related to the digestive system is compelling physicians to utilize novel therapeutic drugs that are more efficient than the traditional ones. In addition, incessant structural improvements in peptide synthesis coupled with development of high-throughput approaches and hybrid mixing of solid and liquid synthesis is partly responsible for the exciting preclinical results shown by new peptide drugs for treating a number of gastrointestinal diseases. Drug makers are also emphasising on enhancing peptide properties, such as stability and half-life to overcome few of the limitations of peptides. In recent years, a lot of progress has been made in developing efficacious peptide therapeutics. Nonetheless, the high complexity of peptides remain a major challenge for manufacturers and hence dampening the surging spirit of the market to a certain extent.

Therapeutic peptides are used to treat various types of cardiovascular diseases. Initially, the development of peptides as therapeutic agents was avoided by the pharmaceutical industry due to their low stability, rate of degradation and poor delivery. However, in the present times, with increasing amounts of economic resources being diverted to healthcare R&D, new avenues have opened up for peptide therapeutics. Increasing healthcare expenditure and increasing FDI in emerging economies along with the emergence of prominent pharmaceutical and biotech companies is fuelling market growth in peptide therapeutics. Besides, growing number of people suffering from cardiovascular diseases is also fuelling the market for peptide therapeutics. Breakthroughs in the development of therapeutic peptides for treating cardiovascular diseases and the development of new peptides is also fuelling the market growth. However, various factors such as increasing cost of developing peptides, rapid metabolism of peptide drugs and a stringent regulatory framework may restrain the growth of therapeutic peptides.

Popularity of peptide based cancer therapeutics is on the rise, owing to the positive outlook on their efficiency in treating cancer. According to the latest report published by Fact.MR, the global market for peptide based cancer therapeutics is set to reflect an above average CAGR during 2017 to 2022, to reach a valuation in excess of US$ 11,100 Mn. Incessant development in drug modification, stability, delivery and preclinical achievements is reflecting positively on the future prospects of the global peptide based cancer therapeutics market. Of late, an array of new peptides with encouraging preclinical results are undergoing clinical trials for treating cancer. At the same time, these new peptide are also finding application in various other therapeutic areas. Also, increasing occurrence of cancer is anticipated to be instrumental in boosting the demand for peptide based cancer therapeutics in the near future. As per WHO, over 8 million deaths were recorder globally due to cancer in 2015. Cancer remains one of the foremost causes of death around the world. Factors mentioned above are projected to make a significant influence on the global market for peptide based cancer therapeutics over the forecast period. Moreover, low potency of conventional cancer therapeutics and the adverse side-effects from these therapeutics is prompting physicians to utilise other options.  This, in turn, is facilitating the adoption of new-age peptide based therapeutic drugs.

Fact.MR, in its new report, estimates the global OTC herbal and traditional medicines market to register a moderate 4.8% CAGR over the forecast period 2017 to 2022. The report anticipates revenues from the global OTC herbal and traditional medicines market to surpass US$ 30,000 Mn by 2022-end.

The global  OTC analgesics market is projected to register an above-average CAGR during 2017 to 2022. Global sales of OTC analgesics is estimated to account for nearly US$ 25,000 Mn revenues by 2022-end.

Growing prevalence of eye disorders and abnormalities has led to surge in demand for optometry equipment globally. In addition, government in various countries are taking initiatives to control visual impairment. Such factors are projected to impact growth of the global optometric equipment market positively. Fact.MR states that the global optometry equipment market is projected to reflect a CAGR of x over the forecast period, 2017-2026.

Growing need for minimally invasive technological devices has led to a surge in demand for neurointerventional devices in the healthcare sector. Moreover, increasing prevalence of vascular diseases is expected to impact growth of the global neurointerventional devices market positively. According to a compiled report, the global neurointerventional devices market will register a healthy CAGR growth over the projected period, 2017 – 2022.

Efficacy of neonatal ventilators in reducing infant mortality continues to drive their adoption in healthcare settings, finds a new Fact.MR study. Global sales are likely to surpass 19,000 units in 2018, equating a market value of over US$ 440 Mn. End-users continue to show a marked affinity for hybrid neonatal ventilators that offer the advantages of both invasive and non-invasive variants.

Fact.MR, in its new report, anticipates the global medical flexible packaging market to register a moderate growth over the forecast period 2017 to 2022. Sales of medical flexible packaging across the globe are expected to account for over US$ 25,000 Mn revenues by 2022-end.

According to a latest research study by Fact.MR the global lewy body dementia treatment market is projected to surpass US$ 3,650 Mn in 2019, up from nearly 3,500 Mn in 2018. Broader factors concerning the healthcare industry, especially renewed focus on managing geriatric and mental health issues, are likely to impact growth of lewy body dementia treatment market.